Overview

The Biotherapeutics Development Unit (BDU) is responsible for the manufacture of clinical grade biological products, and is part of Cancer Research UK's Drug Development Office. 

The unit is run to Current Good Manufacturing Practice (cGMP) and has a license issued by the Medicines and Healthcare Products Regulatory Authority (MHRA) for the manufacture of investigational medicinal products (IMPs).

The BDU has the capability to manufacture plasmid DNA, monoclonal antibodies and recombinant proteins. The development department provides an efficient means of scaling up the manufacture of research products. 

The QC section carries out all the necessary quality control testing to ensure the quality, safety and efficacy of the product, and has the ability to develop new and existing assays to meet customers' needs.